Study Summary
This trial is testing whether a new way to do a stem cell transplant, which uses a device to remove some cells from the transplanted blood, is safe and effective in children and young adults with cancer or other blood disorders.
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 4 Secondary · Reporting Duration: 1 year
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
1 Treatment Group
TCRαβ+/CD19+ depleted HSCT
1 of 1
Experimental Treatment
80 Total Participants · 1 Treatment Group
Primary Treatment: TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT) · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age Any Age · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are there any opportunities to enroll in this medical trial currently available?
"This trial, which has been advertised since September 16th 2019 and recently updated on the 21st of September 2021, is now actively seeking participants." - Anonymous Online Contributor
To what extent is TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT) a safe procedure for people?
"The safety of TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT) was assessed as a 2, since there is preliminary data that suggests its safety but no evidence to back efficacy." - Anonymous Online Contributor
What is the current aggregate of participants in this medical experiment?
"Correct. According to the information posted on clinicaltrials.gov, this study is actively seeking participants with an initial posting date of September 16th 2019 and a recent update as of September 21st 2021. 80 patients must be enrolled from one medical site for the trial to move forward." - Anonymous Online Contributor